1. Flow cytometry 'Ogata score' for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience
- Author
-
Maria Belen Venegas, Juan Carlos Serrano, Viviana Fanessi, Carlos R. Hernandez‐Perez, Diego Issouribehere, Matilde Boada, Renée Crisp, Romina Guevara, J. Gonzalez, Daniela Lens, Joyce Rico Vido, Alicia Enrico, Natalia Trias, Elvira Deolinda Rodrigues Pereira Velloso, Andreína Burgnini, Sofía Grille Montauban, Fernanda Gonçalves Pereira Cunha, Nydia Strachman Bacal, Viviana Novoa, Valeria Cismondi, Liliana Solari, Laura J. Rabelo‐Carrasco, Irene Lorand-Metze, and Andrea Novoa
- Subjects
Adult ,Male ,medicine.medical_specialty ,Clinical Biochemistry ,Ring sideroblasts ,030204 cardiovascular system & hematology ,Real life setting ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Myelodysplastic syndromes ,Biochemistry (medical) ,Hematology ,General Medicine ,Middle Aged ,Flow Cytometry ,medicine.disease ,Cross-Sectional Studies ,Latin America ,Myelodysplastic Syndromes ,Female ,business ,030215 immunology - Abstract
INTRODUCTION Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The "Ogata score" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the "Ogata score" for the diagnosis of MDS among Latin America (LA) Laboratories. METHODS This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata score" was calculated. RESULTS The sensitivity of "Ogata score" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients "without MDS specific markers" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5). CONCLUSIONS The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.
- Published
- 2019
- Full Text
- View/download PDF